Computable Phenotype Implementation for a National, Multicenter Pragmatic Clinical Trial: Lessons Learned From ADAPTABLE.
aspirin
electronic health records
heart disease
patient selection
pragmatic clinical trial
Journal
Circulation. Cardiovascular quality and outcomes
ISSN: 1941-7705
Titre abrégé: Circ Cardiovasc Qual Outcomes
Pays: United States
ID NLM: 101489148
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
pubmed:
30
5
2020
medline:
22
6
2021
entrez:
30
5
2020
Statut:
ppublish
Résumé
Many large-scale cardiovascular clinical trials are plagued with escalating costs and low enrollment. Implementing a computable phenotype, which is a set of executable algorithms, to identify a group of clinical characteristics derivable from electronic health records or administrative claims records, is essential to successful recruitment in large-scale pragmatic clinical trials. This methods paper provides an overview of the development and implementation of a computable phenotype in ADAPTABLE (Aspirin Dosing: a Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness)-a pragmatic, randomized, open-label clinical trial testing the optimal dose of aspirin for secondary prevention of atherosclerotic cardiovascular disease events. A multidisciplinary team developed and tested the computable phenotype to identify adults ≥18 years of age with a history of atherosclerotic cardiovascular disease without safety concerns around using aspirin and meeting trial eligibility criteria. Using the computable phenotype, investigators identified over 650 000 potentially eligible patients from the 40 participating sites from Patient-Centered Outcomes Research Network-a network of Clinical Data Research Networks, Patient-Powered Research Networks, and Health Plan Research Networks. Leveraging diverse recruitment methods, sites enrolled 15 076 participants from April 2016 to June 2019. During the process of developing and implementing the ADAPTABLE computable phenotype, several key lessons were learned. The accuracy and utility of a computable phenotype are dependent on the quality of the source data, which can be variable even with a common data model. Local validation and modification were required based on site factors, such as recruitment strategies, data quality, and local coding patterns. Sustained collaboration among a diverse team of researchers is needed during computable phenotype development and implementation. The ADAPTABLE computable phenotype served as an efficient method to recruit patients in a multisite pragmatic clinical trial. This process of development and implementation will be informative for future large-scale, pragmatic clinical trials. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02697916.
Sections du résumé
BACKGROUND
Many large-scale cardiovascular clinical trials are plagued with escalating costs and low enrollment. Implementing a computable phenotype, which is a set of executable algorithms, to identify a group of clinical characteristics derivable from electronic health records or administrative claims records, is essential to successful recruitment in large-scale pragmatic clinical trials. This methods paper provides an overview of the development and implementation of a computable phenotype in ADAPTABLE (Aspirin Dosing: a Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness)-a pragmatic, randomized, open-label clinical trial testing the optimal dose of aspirin for secondary prevention of atherosclerotic cardiovascular disease events.
METHODS AND RESULTS
A multidisciplinary team developed and tested the computable phenotype to identify adults ≥18 years of age with a history of atherosclerotic cardiovascular disease without safety concerns around using aspirin and meeting trial eligibility criteria. Using the computable phenotype, investigators identified over 650 000 potentially eligible patients from the 40 participating sites from Patient-Centered Outcomes Research Network-a network of Clinical Data Research Networks, Patient-Powered Research Networks, and Health Plan Research Networks. Leveraging diverse recruitment methods, sites enrolled 15 076 participants from April 2016 to June 2019. During the process of developing and implementing the ADAPTABLE computable phenotype, several key lessons were learned. The accuracy and utility of a computable phenotype are dependent on the quality of the source data, which can be variable even with a common data model. Local validation and modification were required based on site factors, such as recruitment strategies, data quality, and local coding patterns. Sustained collaboration among a diverse team of researchers is needed during computable phenotype development and implementation.
CONCLUSIONS
The ADAPTABLE computable phenotype served as an efficient method to recruit patients in a multisite pragmatic clinical trial. This process of development and implementation will be informative for future large-scale, pragmatic clinical trials. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02697916.
Identifiants
pubmed: 32466729
doi: 10.1161/CIRCOUTCOMES.119.006292
pmc: PMC7321832
mid: NIHMS1589988
doi:
Substances chimiques
Platelet Aggregation Inhibitors
0
Aspirin
R16CO5Y76E
Banques de données
ClinicalTrials.gov
['NCT02697916']
Types de publication
Clinical Trial Protocol
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e006292Subventions
Organisme : AHRQ HHS
ID : K12 HS026385
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001422
Pays : United States
Références
J Am Med Inform Assoc. 2013 Jan 1;20(1):144-51
pubmed: 22733976
Contemp Clin Trials Commun. 2018 Mar 09;10:42-49
pubmed: 29696157
Med Care. 2013 Aug;51(8 Suppl 3):S30-7
pubmed: 23774517
Contemp Clin Trials Commun. 2018 Nov 10;12:154-160
pubmed: 30480162
J Am Med Inform Assoc. 2013 Jan 1;20(1):117-21
pubmed: 22955496
J Am Med Inform Assoc. 2013 Dec;20(e2):e226-31
pubmed: 23956018
Am Heart J. 2013 Jun;165(6):837-47
pubmed: 23708153
J Biomed Inform. 2013 Oct;46(5):830-6
pubmed: 23820016
J Am Med Inform Assoc. 2017 Sep 1;24(5):996-1001
pubmed: 28340241
J Biomed Inform. 2004 Jun;37(3):147-61
pubmed: 15196480
Ann Intern Med. 2009 Sep 1;151(5):359-60
pubmed: 19638404
Ann Intern Med. 2015 Oct 20;163(8):635-6
pubmed: 26301537
EGEMS (Wash DC). 2018 Apr 13;6(1):3
pubmed: 29881761
J Am Coll Cardiol. 2016 Oct 25;68(17):1898-1907
pubmed: 27765193
Circulation. 2017 Sep 26;136(13):1207-1216
pubmed: 28687707
J Biomed Inform. 2010 Jun;43(3):451-67
pubmed: 20034594
Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:1-8
pubmed: 22262586
Med Care. 2012 Jul;50 Suppl:S21-9
pubmed: 22692254
Artif Intell Med. 2016 Jul;71:57-61
pubmed: 27506131
Int J Qual Health Care. 2012 Jun;24(3):200-5
pubmed: 22490301
EGEMS (Wash DC). 2014 Jul 11;2(1):1079
pubmed: 25848594
Stud Health Technol Inform. 2015;216:574-8
pubmed: 26262116
Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:12-7
pubmed: 22262588
N Engl J Med. 2014 Jun 5;370(23):2165-7
pubmed: 24897081
J Am Med Inform Assoc. 2017 Nov 1;24(6):1062-1071
pubmed: 28379377
EGEMS (Wash DC). 2016 Jul 05;4(3):1232
pubmed: 27563686
BMC Med Inform Decis Mak. 2019 Apr 4;19(Suppl 3):78
pubmed: 30943974
J Am Med Inform Assoc. 2013 Dec;20(e2):e206-11
pubmed: 24302669
BMC Med Res Methodol. 2017 Sep 18;17(1):144
pubmed: 28923013
CMAJ Open. 2019 Feb 3;7(1):E23-E32
pubmed: 30718353
Clin Trials. 2010 Apr;7(2):183-9
pubmed: 20338903
BMC Med Inform Decis Mak. 2013 Mar 21;13:37
pubmed: 23514203